IMR Press / CEOG / Volume 43 / Issue 4 / DOI: 10.12891/ceog3003.2016

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
The clinical significance of CA19-9 in ovarian mature cystic teratoma
Show Less
1 Department of Gynecology and Obstetrics, the First Affiliated Hospital of GuangXi Medical University, NanNing City (China)
Clin. Exp. Obstet. Gynecol. 2016, 43(4), 522–525; https://doi.org/10.12891/ceog3003.2016
Published: 10 August 2016
Abstract

Objective: To evaluate the clinical significance of CA19-9 in patients with ovarian mature cystic teratoma (MCT). Materials and Methods: A retrospective study was performed on 65 patients with pathologically-confirmed MCT and 80 patients with benign epithelial ovarian tumors. Serum tumor markers for all patients and tissue CA19-9 for MCTs were measured. The relationships between clinical characteristics of MCTs and CA19-9, as well as the correlation between serum and tissue level of CA19-9 in MCTs, were evaluated. Results: The mean serum level of CA19-9 in MCTs was significantly higher than that in benign ovarian epithelial tumors (49.9 ± 73.4 IU/ml vs. 17.08 ± 24.8 IU/ml). CA19-9 was the only tumor marker with a mean serum level above the cut-off value and the elevation rate was 30.76% in MCTs. The positive tissue expression rate of CA19-9 in MCT patients were 50.9 % and were higher than that of preoperative serum levels (50.9% vs. 32.7%). Conclusion: Serum CA19-9 has the highest positivity rate among other tumor markers in MCT. Elevated serum CA19-9 is not an uncommon finding MCT and could be used as a marker in the differential diagnosis of MCT in patients with pelvic mass.
Keywords
Mature cystic teratoma
Ovarian epithelial tumor
CA19-9
Tumor marker
Share
Back to top